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Introduction {#sec005}
============

Overcrowding of emergency departments (ED) has become a worldwide challenge \[[@pone.0155363.ref001]\]. International measures of ED crowding have demonstrated a steady increase of ED visits over the past few decades \[[@pone.0155363.ref002]\]. In the United States (US) e.g., there has been an enormous increase in ED visits, coinciding with a downsizing in the number of ED institutions and consecutively longer ED lengths of stay (LOS). This was called a major problem ("national epidemic") by the Institute of Medicine in 2006 \[[@pone.0155363.ref003]\]. Previously descripted reasons for crowding ED are multifaceted, e.g. involving non-urgent visits, "frequent-flyer" patients, influenza season, inadequate staffing, inpatient boarding, and hospital bed shortages \[[@pone.0155363.ref004]\]. Over the past 20 years, patients arriving in the ED have faced increasingly long average wait times, resulting in extended ED visit lengths \[[@pone.0155363.ref005]--[@pone.0155363.ref007]\]. Most important, these increases have been most pronounced for patients with severe, acute, and critical illnesses such as myocardial infarction and severe infections \[[@pone.0155363.ref005], [@pone.0155363.ref006], [@pone.0155363.ref008]\]. Focusing on acute infections, ED crowding was described to be associated with delayed and non-receipt of antibiotics in patients admitted with community-acquired pneumonia \[[@pone.0155363.ref009], [@pone.0155363.ref010]\].

Investigating specific components and process steps, recently, a French group found significant associations between age and triage priority and the ED LOS of patients discharged from the ED \[[@pone.0155363.ref011]\]. Further literature has investigated the human toll of ED crowding, demonstrating relationships between crowding and negative patient-relevant outcomes, including poorer care, adverse events, medication errors and lower satisfaction \[[@pone.0155363.ref012]--[@pone.0155363.ref015]\].

The main purpose of this study was to perform a prospective international analysis of factors being associated with delayed administration of antibiotic therapy and ED care in patients with an acute infection requiring appropriate (e.g. antibiotic) therapy.

Methods {#sec006}
=======

Study design and setting {#sec007}
------------------------

We prospectively performed an observational cohort study of unselected adult medical admissions through the ED of three tertiary care hospitals in Switzerland, France, and US between March and October 2013. The Swiss hospital (Kantonsspital Aarau) is a 600-bed tertiary care hospital with most medical admissions entering the hospital over the ED. The French hospital (Hopital Pitié-Salpêtrière, Paris) is a large inner-city 1800-bed referral academic centre. The US hospital (Morton Plant Hospital, Clearwater, Florida) is a 687-bed community referral centre. As an observational quality control study, the Institutional Review Boards (IRB) of the three hospitals approved the study and waived the need for individual informed consent (main Swiss IRB: Ethikkommission Kanton Aargau (EK 2012/059); French IRB: CCTIRS---Le Comité consultatif sur le traitement de l\'information en matière de recherche (C.C.T.I.R.S.) (CPP ID RCB: 2013-A00129-36); US IRB MPM-SAH Institutional Review Board, Clearwater Florida \[IRB number 2013_005\]). The study was registered at the ClinicalTrials.gov registration website (<http://www.clinicaltrials.gov/ct2/show/NCT01768494>) and the study protocol has been published previously \[[@pone.0155363.ref016]\] as well as the main analysis \[[@pone.0155363.ref017]\].

Data collection and processing {#sec008}
------------------------------

We included all consecutive medical ED patients with a history of an acute infection. Patients presenting to the surgical ward and patients \<18 years of age were excluded. All procedures were carried out as part of standard patient care. In all patients, we recorded type of infection, collected clinical parameters, pertinent initial vital signs, and laboratory values. Urinary tract infections comprised cystitis, pyelonephritis, prostatitis. Gastrointestinal tract infections mostly comprised gastroenteritis, biliary tract infections, and pancreatitis. Erysipelas displayed the largest part of skin infections, followed by cellulitis. Socio-demographic data were available using routinely gathered information from the hospital electronic medical system used for coding of diagnosis-related groups (DRG) codes. ED nurses were involved making an electronically note of ED care timeliness that included waiting time (time of arrival to time seen by a health care professional), time to drug (time of arrival to time of first drug application) and length of ED stay (LOS, time of arrival to time leaving the ED).

Statistical analysis {#sec009}
--------------------

We used descriptive statistics including mean with standard deviation, median with interquartile range (IQR) and frequencies on each ED measure. Patients were divided in three groups depending on national setting. To identify independent relationship between hospital- and patient characteristics and ED timeliness univariate regression models were used to assess possible predictors that were further analysed in multivariable models (adjusted for type of infection, age, gender, vital signs, laboratory values \[infection/inflammation, renal, electrolytes\], comorbidities) using 95% confidence intervals (CIs). In case of a dichotomous factor (e.g. no tumor, tumor), the absence of the factor was chosen as reference. In case of a multi-level factor (e.g. infections), the most common one (e.g. pneumonia) was set as reference. Tests were carried out at 5% significance levels. Analyses were performed with STATA 12.1 (Stata Corp., College Station, TX, USA).

Results {#sec010}
=======

Population {#sec011}
----------

A total of 544 medical ED patients with a history of an acute infection were included (median age 66 years, 49.3% male gender). The main type of infection at ED admission was pneumonia (40.1%), followed by urinary tract (UTI) (25.9%) and gastrointestinal infections (10.7%). Hypertension (34.6%), diabetes (16.7%), and renal failure (15.8%) were the main comorbidities. 47.2% of patients had two or more criteria for a systematic inflammatory response syndrome (SIRS) and tended to have elevated inflammatory biomarker. A detailed country specific baseline information is visualised in [Table 1](#pone.0155363.t001){ref-type="table"}.

10.1371/journal.pone.0155363.t001

###### Baseline characteristics.

![](pone.0155363.t001){#pone.0155363.t001g}

  Parameter                                       International (n = 544)   CH (n = 213)        F (n = 195)         US (n = 136)        p-value
  ----------------------------------------------- ------------------------- ------------------- ------------------- ------------------- ---------
  **Demographics**                                                                                                                      
  Age, median (IQR), yr                           66.0 (50.0--79.0)         69.0 (56.0--78.0)   57.0 (38.0--68.0)   76.0 (58.0--84.0)   \<0.001
  Male, No (%)                                    268 (49.3)                125 (58.7)          95 (48.7)           48 (35.3)           \<0.001
  **Type of infection, No (%)**                                                                                                         
  Pneumonia                                       218 (40.1)                120 (56.3)          49 (25.1)           49 (36.0)           \<0.001
  Urinary tract infection                         141 (25.9)                9 (4.2)             84 (43.1)           48 (35.3)           
  Gastrointestinal tract infection                58 (10.7)                 29 (13.6)           22 (11.3)           7 (5.1)             
  Skin infection                                  53 (9.7)                  32 (15.0)           17 (8.7)            4 (2.9)             
  Others                                          74 (13.6)                 23 (10.8)           23 (11.8)           28 (20.6)           
  **Comorbidities, No (%)**                                                                                                             
  Gastrointestinal disease                        97 (17.8)                 59 (27.7)           25 (12.8)           13 (9.6)            \<0.001
  Coronary artery disease                         29 (5.3)                  16 (7.5)            12 (6.2)            1 (0.7)             0.019
  Congestive heart failure                        36 (6.6)                  20 (9.4)            5 (2.6)             11 (8.1)            0.016
  Hypertension                                    188 (34.6)                100 (46.9)          41 (21.0)           47 (34.6)           \<0.001
  Chronic obstructive pulmonary disease           47 (8.6)                  27 (12.7)           17 (8.7)            3 (2.2)             0.003
  Diabetes mellitus                               91 (16.7)                 38 (17.8)           26 (13.3)           27 (19.9)           0.25
  Renal failure                                   86 (15.8)                 58 (27.2)           13 (6.7)            15 (11.0)           \<0.001
  Tumor                                           45 (8.3)                  17 (8.0)            21 (10.8)           7 (5.1)             0.180
  **Clinical findings**                                                                                                                 
  Heart rate, median (IQR), beats/min             92 (78--107)              91 (78--105)        95 (78--109)        91 (78--111)        0.440
  Body temperature, median (IQR), °C              37.3 (36.7--38.1)         37.8 (37.1--38.6)   37.2 (36.7--37.9)   36.8 (36.3--37.3)   \<0.001
  Oxygen saturation, median (IQR), %              96 (93--98)               94 (91--97)         98 (95--99)         96 (93--98)         \<0.001
  Systolic blood pressure, median (IQR), mmHg     130 (115--148)            133 (118--148)      127 (115--144)      131 (112--155)      0.180
  Diastolic blood pressure, median (IQR), mmHg    76 (65--87)               76 (67.5--87)       76 (67--87)         74 (62--85)         0.150
  SIRS: 0/1 criteria, No (%)                      287 (52.8)                92 (43.2)           109 (55.9)          86 (63.2)           \<0.001
  SIRS: 2--4 criteria, No (%)                     257 (47.2)                121 (56.8)          86 (44.1)           50 (36.8)           
  **Initial laboratory findings, median (IQR)**                                                                                         
  White blood cells count, cells x 10^9^/L        10.9 (7.5--14.5)          11.2 (8.1--14.5)    10.9 (7.1--14.7)    10.1 (7.5--14.1)    0.470
  C-reactive protein, mg/dL                       110 (30--231)             103 (33.8--171)     21 (3--85)          108.5 (26.5--238)   \<0.001
  Sodium, mmol/L                                  137 (134--139)            137 (134--139)      137 (135--139)      138 (135.5--140)    0.019
  Glucose, mmol/L                                 6.5 (5.6--8.2)            6.5 (5.8--8.2)      6.2 (5.6--8)        4.8 (4.3--5.3)      0.570
  Creatinine, μmol/L                              86 (67--116)              99 (79--140)        69 (55--93)         88 (71--133)        \<0.001

CH, Switzerland; F, France; US, United States of America; IQR, interquartile range; SIRS, Systemic Inflammatory Response Syndrome.

Time to start medication {#sec012}
------------------------

In general, median time to antibiotic administration was 214 minutes (95% CI: 199, 228), with a maximum of 307 minutes; 95% CI: 263, 328) in France, 230 minutes (95% CI: 210, 264) in Switzerland, and 161 minutes (95% CI: 144, 170) in the US. When looking at gastrointestinal infections in the overall cohort (international), median time to drug (326 minutes \[95% CI: 284, 372\]) was significantly (p\<0.001 \[ANOVA\]) increased compared to more localised infections such as pneumonia (209 minutes \[95% CI: 192, 228\]), UTI (204 minutes \[95% CI: 169, 233\]), and skin infections (207 minutes \[95% CI: 168, 253\]) ([Table 2](#pone.0155363.t002){ref-type="table"}). We also found significant differences in time to discharge when comparing different infection sites in the overall patient cohort (p = 0.001 \[ANOVA\]). This was mainly due to patients from the Swiss centre. No differences were observed in time to first physician contact among different infections. Consistently, in all subgroups of acute infections, we found highly significant time differences in starting antibiotics between European and US hospitals.

10.1371/journal.pone.0155363.t002

###### Timeliness of ED care.

![](pone.0155363.t002){#pone.0155363.t002g}

                                                                International (n = 544)    CH (n = 213)               F (n = 195)                US (n = 136)               
  ---------------------------------- -------------------------- -------------------------- -------------------------- -------------------------- -------------------------- ---------
  **Overall infections (n = 531)**   First physician contact    55 (49, 57); 1, 350        62 (59, 69); 6, 350        67 (55, 77); 4, 195        19 (16, 22); 1, 165        \<0.001
                                     Medication (antibiotics)   214 (199, 228); 26, 476    230 (210, 264); 69, 476    307 (263, 328); 51, 474    161 (144, 170); 26, 425    \<0.001
                                     ED discharge               322 (308, 335); 69, 718    361 (346, 382); 150, 718   319 (300, 340); 69, 653    260 (245, 274); 124, 638   \<0.001
  **Pneumonia (n = 218)**            First physician contact    53 (44, 58); 1, 350        61 (57, 67); 6, 350        58 (42, 82); 4, 177        21 (14, 23); 1, 136        \<0.001
                                     Medication (antibiotics)   209 (192, 228); 26, 474    220 (200, 252); 77, 465    310 (220, 359); 51, 474    141 (124, 162); 26, 371    \<0.001
                                     ED discharge               326 (303, 344); 69, 698    350 (331, 367); 167, 698   326 (268, 359); 69, 580    249 (221, 276); 124, 497   \<0.001
  **UTI (n = 141)**                  First physician contact    49 (39, 60); 1, 329        57 (12, 182); 12, 329      78 (63, 88); 13, 195       18 (15, 24); 1, 125        \<0.001
                                     Medication (antibiotics)   204 (169, 233); 69, 447    246 (142, 345); 97, 377    314 (221, 339); 69, 447    165 (145, 182); 88, 394    \<0.001
                                     ED discharge               294 (274, 318); 75, 639    434 (273, 527); 254, 572   311 (292, 340); 75, 639    247 (224, 268); 143, 523   0.001
  **GIT (n = 58)**                   First physician contact    60 (51, 67); 8, 345        64 (57, 82); 25, 345       52 (34, 70); 17, 130       14 (9, 119); 8, 127        0.032
                                     Medication (antibiotics)   326 (284, 372); 93, 476    330 (295, 374); 93, 476    369 (311, 396); 311, 396   228 (218, 248); 218, 248   0.213
                                     ED discharge               389 (354, 440); 133, 718   441 (383, 478); 244, 718   374 (299, 440); 133, 653   318 (175, 398); 135, 410   0.027
  **Skin infections (n = 53)**       First physician contact    60 (54, 83); 3, 304        74 (57, 114); 13, 304      54 (47, 86); 24, 123       35 (3, 55); 3, 55          0.040
                                     Medication (antibiotics)   207 (168, 253); 69, 468    189 (159, 245); 69, 414    242 (144, 463); 109, 468   257 (250, 264); 250, 264   0.231
                                     ED discharge               327 (287, 362); 135, 590   325 (278, 365); 150, 581   357 (279, 424); 135, 590   267 (189, 359); 189, 359   0.146
  **Other infections (n = 74)**      First physician contact    46 (28, 67); 3, 299        71 (55, 110); 8, 299       70 (32, 88); 9, 153        19 (16, 37); 3, 165        0.002
                                     Medication (antibiotics)   187 (169, 238); 39, 473    234 (181, 334); 90, 473    248 (70, 371); 69, 380     165 (129, 199); 39, 425    0.077
                                     ED discharge               317 (278, 362); 86, 711    412 (368, 530); 177, 711   282 (213, 368); 86, 613    284 (258, 329); 186, 638   0.012

CH, Switzerland; F, France; US, United States of America; CI, confidence interval; UTI, urinary tract infection; GIT, gastrointestinal tract infection; ED, emergency department.

Timeliness of ED care {#sec013}
---------------------

As shown in [Fig 1](#pone.0155363.g001){ref-type="fig"} and [Table 2](#pone.0155363.t002){ref-type="table"}, the overall median waiting time to the first physician contact was 55 minutes (95% CI: 49, 57), notably, there were large differences between the two European hospitals (62 and 67 minutes in Switzerland and France, respectively) and the US hospital (19 minutes; 95% CI: 16, 22). Analog to above mentioned differences in time to start antibiotic therapy, this trend was also obvious investigating subgroups of infections. Finally, international median ED LOS was 322 minutes (95% CI: 308, 335), with a maximum in Switzerland (361 minutes; 95% CI: 346, 382), followed by France (319 minutes; 95% CI: 300, 340), and the US with 260 minutes (95% CI: 245, 274). Corresponding to median time to antibiotics, median ED LOS was larger in gastrointestinal infections than in other infection subgroups. Notable, in French patients with UTI, median time to antibiotic therapy was longer than median ED LOS, resulting from delayed drug administration in clinically stable patients only after ED discharge to the medical ward. All results in detail are shown in [Table 2](#pone.0155363.t002){ref-type="table"}.

![Distribution of ED measures of timely care in patients with acute infections across different countries.\
The bottom and top of the box represent the 25th and 75th percentiles of the hospital-reported mean times for that measure, with the middle line representing the median. \* Time of arrival to time seen by a doctor. \*\* Time of arrival to time being given medication. \*\*\* Time of arrival to time leaving the emergency department for home or for an in-hospital bed.](pone.0155363.g001){#pone.0155363.g001}

Predictors for delayed antibiotic drug administration {#sec014}
-----------------------------------------------------

As shown in [Table 3](#pone.0155363.t003){ref-type="table"}, using multivariable adjusted regression analyses, existence of a gastrointestinal tract infection was a significant predictive parameter for delayed start of therapy compared to patients with pneumonia, whereas patients with more localised skin infections, such as erysipelas, tended to results in faster drug administration (e.g. in Switzerland). Focusing demographic characteristics, Swiss patients with an age between 66 and 79 years tended to be at risk for a later onset of adequate therapy using univariate analyses. However, older US patients were treated earlier than younger ones. In multivariable regression models these effects could not be substantiated. Additionally, Swiss patients with a larger inflammation (more positive SIRS criteria) or a chronic obstructive pulmonary disease (COPD) showed a decreased time to first drug administration. In France, diabetic patients and patients with a hyperglycaemia had to wait longer for an appropriate anti-infective therapy compared to non-diabetic ones. Finally, patients entering the ED during "rush hours" (6--12 pm) tended to wait longer for an appropriate medication.

10.1371/journal.pone.0155363.t003

###### Predictors of delayed antibiotic drug administration.

![](pone.0155363.t003){#pone.0155363.t003g}

  Predictor                         International (n = 544)             CH (n = 213)                   F (n = 195)              
  --------------------------------- ------------------------- --------- ---------------------- ------- ------------------------ -------
  **Pneumonia**                     reference                 \-        reference              \-      reference                \-
  **UTI**                           40.7 (-13.0--94.4)        0.137     7.0 (-89.2--103.2)     0.886   163.6 (-163.3--490.4)    0.308
  **GIT**                           119.5 (58.0--181.0)       \<0.001   92.6 (34.4--150.9)     0.002   267.3 (-151.5--686.0)    0.197
  **Skin infections**               -46.5 (-101.0--8.0)       0.094     -65.5 (-118.9--12.1)   0.016   35.6 (-311.1--382.2)     0.832
  **Other infections**              31.2 (-33.3--95.8)        0.341     1.1 (-62.0--64.3)      0.972   82.9 (-311.7--477.5)     0.665
  **Age ≤50y**                      reference                 \-        reference              \-      reference                \-
  **Age ≤66y**                      10.4 (-47.5--68.4)        0.724     35.8 (-25.1--96.6)     0.248   -295.1 (-487.4--102.8)   0.005
  **Age ≤79y**                      23.3 (-33.9--80.5)        0.423     30.7 (-29.8--91.2)     0.318   -87.1 (-294.1--119.8)    0.389
  **Age \>79y**                     -36.6 (-103.9--30.6)      0.284     -28.5 (-99.3--42.3)    0.428   -120.3 (-403.7--163.1)   0.385
  **Female**                        reference                 \-        reference              \-      reference                \-
  **Male**                          -12.8 (-53.7--28.1)       0.538     -15.8 (-58.0--26.4)    0.461   43.1 (-130.6--216.7)     0.610
  **Day time 0--6 am**              reference                 \-        reference              \-      reference                \-
  **Day time 6--12 am**             26.6 (-55.8--109.0)       0.525     4.9 (-73.7--83.4)      0.903   -17.8 (-162.1--126.4)    0.798
  **Day time 0--6 pm**              22.2 (-59.0--103.5)       0.59      21.9 (-53.8--97.6)     0.568   NA                       NA
  **Day time 6--12 pm**             39.5 (-44.2--123.2)       0.354     38.8 (-37.6--115.1)    0.318   NA                       NA
  **0 SIRS criteria**               reference                 \-        reference              \-      reference                \-
  **1 SIRS criteria**               -35.8 (-94.5--23.3)       0.235     -38.0 (-96.0--19.9)    0.197   -49.9 (-290.8--191.0)    0.669
  **2 SIRS criteria**               -24.0 (-82.7--34.6)       0.42      -26.8 (-87.1--33.5)    0.382   64.2 (-206.7--335.1)     0.626
  **3/4 SIRS criteria**             -59.1 (-120.9--2.6)       0.06      -60.7 (-123.3--2.0)    0.058   98.4 (-195.3--392.1)     0.492
  **≤130mmHg systolic**             reference                 \-        reference              \-      reference                \-
  **\>130mmHg systolic**            11.1 (-32.1--54.2)        0.614     9.9 (-34.0--53.8)      0.656   -164.3 (-391.3--62.4)    0.146
  **≤76mmHg diastolic**             reference                 \-        reference              \-      reference                \-
  **\>76mmHg diastolic**            -5.7 (-49.7--38.3)        0.799     9.4 (-34.1--52.9)      0.669   57.0 (-121.9--236.0)     0.513
  **Sodium (136--146mmol/L)**       reference                 \-        reference              \-      reference                \-
  **Sodium (\<136, \>146mmol/L)**   -21.9 (-61.9--18.1)       0.281     -20.4 (-60.3--19.5)    0.315   -23.8 (-205.3--157.6)    0.786
  **Glucose (4--7mmol/L)**          reference                 \-        reference              \-      reference                \-
  **Glucose (\<4, \>7mmol/L)**      -26.6 (-67.9--14.6)       0.205     -17.6 (-60.8--25.5)    0.421   203.0 (-2.1--408.2)      0.052
  **Creatinine (≤86mg/L)**          reference                 \-        reference              \-      reference                \-
  **Creatinine (\>86mg/L)**         21.4 (-24.3--67.2)        0.357     6.8 (-40.1--53.6)      0.776   43.7 (-130.0--217.4)     0.604
  **CRP (≤69mg/L)**                 reference                 \-        reference              \-      reference                \-
  **CRP (\>69mg/L)**                13.3 (-25.7--52.3)        0.502     1.6 (-37.9--41.2)      0.935   58.9 (-98.6--216.4)      0.443
  **No obesity**                    reference                 \-        reference              \-      reference                \-
  **Obesity**                       -11.2 (-70.0--47.5)       0.707     0.1 (-54.1--54.3)      0.998   NA                       NA
  **No CAD**                        reference                 \-        reference              \-      reference                \-
  **CAD**                           -13.6 (-83.4--56.1)       0.701     11.7 (-57.0--80.3)     0.738   -137.7 (-476.1--200.7)   0.405
  **No CHF**                        reference                 \-        reference              \-      reference                \-
  **CHF**                           27.7 (-39.3--94.6)        0.417     22.0 (-42.6--86.6)     0.502   239.6 (-255.5--734.6)    0.324
  **No COPD**                       reference                 \-        reference              \-      reference                \-
  **COPD**                          -44.7 (-101.3--11.8)      0.12      -66.2 (-120.2--12.3)   0.016   -51.1 (-421.1--319.0)    0.776
  **No tumor**                      reference                 \-        reference              \-      reference                \-
  **Tumor**                         27.6 (-35.1--90.2)        0.387     40.4 (-26.1--106.9)    0.232   -75.0 (-339.2--189.1)    0.559
  **No diabetes**                   reference                 \-        reference              \-      reference                \-
  **Diabetes**                      27.8 (-23.5--79.1)        0.287     -9.1 (-64.6--46.5)     0.747   222.3 (-0.5--445.0)      0.050
  **No GIT disease**                reference                 \-        reference              \-      reference                \-
  **GIT disease\***                 -1.6 (-46.3--43.0)        0.942     -8.0 (-50.4--34.3)     0.709   252.0 (-36.1--540.0)     0.083
  **No hypertension**               reference                 \-        reference              \-      reference                \-
  **Hypertension**                  29.4 (-10.4--69.3)        0.146     38.0 (-1.8--77.9)      0.061   19.3 (-168.0--206.6)     0.831
  **No renal failure**              reference                 \-        reference              \-      reference                \-
  **Renal failure**                 -30.3 (-79.0--18.3)       0.22      -12.6 (-61.3--36.1)    0.609   -59.6 (-297.9--178.7)    0.607

CH, Switzerland; F, France; US, United States of America; CI, confidence interval; UTI, urinary tract infection; GIT, gastrointestinal tract; SIRS, systemic inflammatory response syndrome; CRP, C-reactive protein; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; NA, not applicable; US data not applicable due to small patient number.

Discussion {#sec015}
==========

In this international prospective observational cohort study of ED patients with a history of an acute infection we compared predictors for delay in initial care. In a second step, timeliness of ED care was investigated. This study was conducted in three tertiary hospitals with a different ED management (e.g. triage system), health care system, and socio-demographic spectrum (e.g. culture, race).

In general, we found a median ED LOS of about 5.5 hours that is higher compared to previously published data in France and the US \[[@pone.0155363.ref011], [@pone.0155363.ref018], [@pone.0155363.ref019]\], in Switzerland there exists no comparable data. The main reason for these observation is that most patients with acute infections have a diffuse and non-specific symptomatic (e.g. fever, shivering, fatigue) and therefore require supplementary time for diagnostic- and therapeutic steps. Most previous publications investigated unselected ED patients independent of discipline, mirroring a fuzzy image of patient subgroups like acute infectious diseases \[[@pone.0155363.ref007], [@pone.0155363.ref020], [@pone.0155363.ref021]\].

Waiting time, time to drug, and ED LOS were shorter in the US compared to the European centres. In addition to a slightly lower acuity and severity of admitted US patients (lower body temperature, less SIRS criteria), and significant differences in socio-demographics of ED patients among all centres (US population was older and more females), implementation of clinical pathways and fast-track admission in the US could be a possible explanation for a superior ED timeliness. Yet, baseline crowding status of the participating hospitals was not available and we can thus not exclude bias in this regard. Such information should be included in future larger trials. Another explanation may relate to the high administrative work associated with ED admission in Switzerland \[[@pone.0155363.ref022]\], resulting in a prolonged time from therapy to ED discharge.

Mainly, the presence of a gastrointestinal tract infection was a significant predictor of a delayed initiation of an adequate therapy, likely because abdominal site infection may be diagnostically more obscure and symptoms masked or atypical. In contrast, more localised infections (e.g. skin infections)--requiring less extended supplementary diagnostics--tended to be treated faster, also resulting in a decreased ED LOS. Severe cases (more positive SIRS criteria, relevant comorbidities such as COPD) were treated significantly faster in the Swiss population. In France, diabetic patients showed longer waiting times, potentially mirroring a more polymorbid (e.g. metabolic syndrome) patient population. Due to small the small number of patients included from the US site, we focused on the comparison of the two European centres.

As a second point, analogous to previous literature \[[@pone.0155363.ref020], [@pone.0155363.ref023], [@pone.0155363.ref024]\], length of stay was increased in Swiss elderly patients, suggesting a higher complexity due to comorbidities and a more prolonged decision-making process than in younger ones. Finally, ED patients presenting between 6:00 and 12:00 p.m. tended to have a longer ED stay, correlating with increased patient admissions \[[@pone.0155363.ref025]\].

Our study has some important limitations. First, this was an observational study that was focusing on the question if an improved initial triage of patients at the earliest stage of ED admission with incorporation of a triage system, initial clinical parameters, vital signs, and prognostic blood markers will improve patient triage \[[@pone.0155363.ref016], [@pone.0155363.ref026]\]. Second, we investigated a small patient sample, with partially incomplete available data, limiting subgroup analyses\`conclusions. Third, we did not take into account the number of medical and non-medical staff, available in these EDs to take care of the patients. Last, we did not consider in-hospital bed capacity that might have had decelerating effects on transfer from the ED to the medical ward. All these limitations could have implications in interpreting our results and may limit external validity. However, we performed an international multicentre study with many available ED parameters, and updated reasons for ED consultation, displaying a major strength of this study.

To further decrease time to first physician contact and time to antibiotics, especially in urgent patients at risk for worse outcome, fast and high sensitive point-of-care testing (POCT) devices measuring prognostic biomarkers could be a promising tool \[[@pone.0155363.ref027]\]. Herein, a new prognostic biomarker (proadrenomedullin, ProADM) \[[@pone.0155363.ref028]\] is supposed to support differentiating urgent from non-urgent patients showing non-conclusive clinical symptoms and to improve existing triage systems. Alternatively, as previously published by Chartier et al., ED flow can be significantly improved by re-purposing a fraction of existing staff, resources, and infrastructure for patients with lower acuity presentations \[[@pone.0155363.ref029]\]. From the initial triages perspective, a recent study that implemented a computer-assisted triage system using acute physiology, pre-existing illness and mobility showed a measurable impact on cost of care for patients with very low risk of death. Patients were safely discharged earlier to their own home and the intervention was cost-effective \[[@pone.0155363.ref030]\]. Finally, another study investigated the effect of implementation of a triage/treatment pathway in adult patients with cancer and febrile neutropenia improving initial ED triage. In this study, antibiotic delays were reduced and quality of care for patients was improved \[[@pone.0155363.ref031]\]. To definitively proof effectiveness and safety of all these promising tools, well-powered large randomized controlled trials are inevitable.

Conclusion {#sec016}
----------

Time to adequate drug administration and ED LOS were principally associated with the clinical picture and the need for diagnostics. In Switzerland, older patients were treated later, suggesting a higher complexity--rudimentary seen in French diabetic patients---with a longer clinical decision-making process than in younger patients. Even, if necessary to optimise evaluation and reach the best final disposition decision, can lengthen the overall time spent in the ED.

This international study provides new insights into the relative effect of diffuse clinical pictures, comorbidities, and demographics on international ED timeliness. Our results suggest that new strategies to reduce time to antibiotic medication and ED LOS--especially in patients with an acute infection---should include suitable advices (e.g. POCT) for ancillary biomarker measurement.
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CI

:   confidence interval

COPD

:   chronic obstructive pulmonary disease

DRG

:   diagnosis-related groups

ED

:   emergency department

IQR

:   interquartile range

LOS

:   length of stay

POCT

:   point-of-care testing

ProADM

:   proadrenomedullin

SIRS

:   systematic inflammatory response syndrome

US

:   United States

UTI

:   urinary tract infection
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